Source: PTSM: Pharmaceutical Technology Sourcing and Management
Issue 6,Volume 3
People on the move.
Duessoldorf, Germany (June 5)–The supervisory board of named Patrik Wohlhauser, currently head of the exclusive synthesis & catalysts business unit, as an executive director of Degussa GmbH. From July 1, 2007, his new responsibilities will include, among others, the new international sales function of RAG's subsidiary Degussa. Wohlhauser will also be the management board member responsible for the Consumer Solutions reporting segment and for the Western and Eastern Europe regions. His successor as head of the exclusive synthesis & catalysts business unit will be Rudolf Hanko, who currently heads the exclusive synthesis business line of the same business unit.
San Diego, CA (June 5)– appointed Catherine J. Hardalo, MD, vice-president of clinical development. Hardalo joins the company from Schering-Plough Research Institute, where she directed the clinical development of antimicrobial products.
San Diego, CA (June 4)–Carol G. Gallagher was promoted to senior vice-president of corporate development and commercial affairs with . Gallagher joined the company as vice-president of commercial affairs in April 2006. She previously served as vice-president of sales, marketing, and product planning at CancerVax Corporation and senior director of oncology marketing at Biogen Idec, Inc.
Mississauga, ON, Canada (May 29)– named Bruce DeChambre vice-president of commercial and business development. DeChambre previously was vice-president of sales and marketing at SAB-Pharma. He also held positions at Abraxis Pharmaceutical, Fujisawa USA, Inc., and Baxter Healthcare Corp.
Indianapolis, IN (May 25)– promoted Frank Deane to president of manufacturing. Deane is currently vice-president of quality. He joined Lilly in 1979 at the company's manufacturing operations in Kinsale, Ireland.
Burlington, MA (May 24)–Robert M. Haggerty was appointed vice-president of quality with Haggerty served as director of quality assurance at Alexion Pharmaceuticals and held various positions at Ben Venue, Dupont, and Transkaryotic Therapies.